Bayer and Veracyte collaborate on precision oncology in thyroid cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bayer and Veracyte have entered a collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer.

Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory who may potentially benefit from biomarker-driven therapies.

“Patients whose thyroid cancer contains actionable alterations and no longer responds to traditional radioactive iodine therapy now have targeted treatment options available to them. Our goal is to identify such patients so physicians can make more informed treatment decisions for their patients,” Bhavesh Ashar, senior vice president and head of U.S. Oncology at Bayer, said in a statement. “With its comprehensive ability to identify broad genomic alterations through its Afirma XA test and its widespread reach among physicians who diagnose thyroid cancer, Veracyte is an ideal collaborator for this program.”

The Afirma XA uses RNA whole-transcriptome sequencing to identify 905 DNA variants and 235 RNA fusions in 593 genes, including novel NTRK fusions, on fine needle aspirates taken from thyroid nodules or lymph nodes.

Through this collaboration, Bayer will provide Afirma XA testing at no cost to all eligible patients when ordered by the physician, regardless of the final results and treatment decision. Additionally, physicians of patients found to harbor NTRK gene fusions as an underlying driver in their thyroid cancer will be alerted of the results. The companies anticipate the program to launch in the first quarter of next year.

Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login